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Abstract
Microarray gene expression data has been used in genome-wide association studies to allow researchers to study gene
regulation as well as other complex phenotypes including disease risks and drug response. To reach scientifically sound
conclusions from these studies, however, it is necessary to get reliable summarization of gene expression intensities. Among
various factors that could affect expression profiling using a microarray platform, single nucleotide polymorphisms (SNPs) in
target mRNA may lead to reduced signal intensity measurements and result in spurious results. The recently released 1000
Genomes Project dataset provides an opportunity to evaluate the distribution of both known and novel SNPs in the
International HapMap Project lymphoblastoid cell lines (LCLs). We mapped the 1000 Genomes Project genotypic data to the
Affymetrix GeneChip Human Exon 1.0ST array (exon array), which had been used in our previous studies and for which gene
expression data had been made publicly available. We also evaluated the potential impact of these SNPs on the
differentially spliced probesets we had identified previously. Though the 1000 Genomes Project data allowed a
comprehensive survey of the SNPs in this particular array, the same approach can certainly be applied to other microarray
platforms. Furthermore, we present a detailed catalogue of SNP-containing probesets (exon-level) and transcript clusters
(gene-level), which can be considered in evaluating findings using the exon array as well as benefit the design of follow-up
experiments and data re-analysis.
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Introduction
Gene expression is an intermediate phenotype that resides
between DNA sequence variation and higher-level cellular or
whole-body phenotypes including disease susceptibility and
individualized drug response. Whole genome expression profiling
using high throughput microarray platforms has been a powerful
tool used by investigators to create a global picture of cellular
function through the quantitative measurement of mRNA of
thousands of genes in parallel. Over the past decade, more than
3,000 scientific publications have reported results using the
Affymetrix GeneChip arrays (Affymetrix, Inc., Santa Barbara,
CA) alone, one of the most frequently used microarray platforms
for expression profiling [1].
A typical gene expression profiling study often involves
measuring and comparing the relative amount of mRNA
expressed in two or more experimental conditions (e.g., normal
and diseased, drug treated and untreated). Notably, several recent
studies using the International HapMap Project (http://www.
hapmap.org/) [2,3] lymphoblastoid cell lines (LCLs) demonstrated
the utility of these microarray platforms in profiling gene
expression and dissecting the genetic architecture of gene
regulation [4]. For example, using the Illumina BeadChip array
(Illumina, Inc., San Diego, CA), Stranger et al. [5,6] profiled and
analyzed ,50,000 transcript targets across the three HapMap
populations: CEU (Caucasian residents of European ancestry from
Utah, USA), YRI (Yoruba people form Ibadan, Nigeria) and ASN
(Han Chinese from Beijing, China and Japanese from Tokyo,
Japan). In contrast, Spielman and co-workers [7] used the
Affymetrix GeneChip Human Genome Focus array to measure
and compare the expression of ,8,000 genes between the CEU
and ASN samples. Taking advantage of the Affymetrix GeneChip
Human Exon 1.0ST array (exon array), which was designed to
interrogate the entire length of the gene and not just the 39 end
characteristic of conventional oligonucleotide arrays, Zhang et al.
measured and compared ,18,000 gene-level transcript clusters [8]
and ,1.4 million exon-level probesets [9] between the CEU and
YRI samples. Using these microarray platforms, significant
differences in gene expression and alternative splicing between
human populations were identified [5–9]. Furthermore, common
genetic variants, particularly, single nucleotide polymorphisms
(SNPs) were found to contribute to a substantial fraction of the
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human populations [5–10]. In addition, genome-wide associations
were performed to identify genetic determinants responsible for
the cytotoxicities to some anticancer drugs (e.g., etoposide [11],
cisplatin [12], carboplatin [13], daunorubicin [14], cytarabine
[15]) by integrating the exon array expression data and genotypic
data on these HapMap samples [16,17].
Although appropriate preprocessing approaches such as the
RMA (robust multichip average) [18] can be used to adjust the
background noise and effects of outliers, identifying expression
differences due to hybridization efficiency is critical. The presence
of sequence polymorphisms (e.g., SNPs) in target mRNA can
cause less efficient hybridization to the microarray probe
compared to a perfectly matched reference sequence, potentially
leading to reduced signal intensity measurements and resulting in
spurious association results [19]. For example, a recent study on
the exon array showed that the effect of SNPs was quite severe and
could lead to considerable false-positive findings [20]. Though in
certain cases, some statistical approaches may be used to detect
and account for this effect (e.g., false cis-acting expression
quantitative trait loci or eQTLs due to polymorphisms in probes
[21]), a comprehensive survey of the SNPs in a microarray
platform, which is the major aim for this work, may provide a
resource to better evaluate the effects of these polymorphisms on
microarray expression data.
To date, the publicly available HapMap I/II genotypic data
[22] have covered .3.1 million common SNPs. Considering the
estimated number of .10 million SNPs in the human genome, it is
expected that there may be more unknown/untyped or rarer
SNPs in these genotyped HapMap samples. Actually, previous
studies have shown that the HapMap genotypic data can not
capture a substantial proportion of untyped SNPs [23–25],
suggesting that deep-resequencing may be needed to uncover
more SNPs in the missing regions [26]. Particularly, an
unprecedented deep-resequencing project launched in 2008, the
1000 Genomes Project (http://www.1000genomes.org/), ambi-
tiously aims to provide a most detailed map of human genetic
variation through genotyping at least 1000 human genomes from
world-wide populations using the next-generation sequencing
technologies [27,28]. The specified aims of this project are to
identify .95% of the variants with allele frequencies .1% in parts
of the human genome that can be sequenced, as well as to identify
.95% of the variants with allele frequencies .0.1–0.5% in exons
(See the 1000 Genomes Project Meeting Report, http://www.
1000genomes.org/bcms/1000_genomes/Documents/1000Genomes-
MeetingReport.pdf). In this study, we present a detailed charac-
terization of SNP-containing probesets (exon-level) and tran-
script clusters (gene-level) of the exon array using the newly
released 1000 Genomes Project genotypic dataset (Figure 1). We
deposited in the public domain the exon array data on the 176
CEU and YRI HapMap samples from our previous studies of
gene expression [8] and transcript isoform variation [9]. We also
m a d ea v a i l a b l er e s u l t s ,u s i n gt h e s eg e n ee x p r e s s i o nd a t a ,f r o m
our eQTL studies (SCAN database at http://www.scandb.org/)
[29] and various pharmacogenomic studies (PACdb at http://
www.pacdb.org/) [30]. This new resource of a comprehensive
catalogue of SNP-containing probesets and transcript clusters on
the exon array can thus help researchers interpret and evaluate
findings based on this platform, facilitate future data re-analysis
efforts, and benefit the design of follow-up experiments. The
same approach can also be applied to other microarray platforms
to allow better evaluation of the potential impact of these
polymorphisms on microarray expression data.
Results
An overview of the methods and major results is provided in
Figure 1.
Figure 1. An overview of the methods and major results. The 1000 Genomes Project genotypic data are mapped to the Affymetrix GeneChip
Human Exon Array 1.0ST. CEU (Caucasians from Utah, USA) and YRI (Yoruba people from Ibadan, Nigeria) are lymphoblastoid cell lines from the
International HapMap Project. Known SNPs are those recorded in the NCBI dbSNP v129 database. Common SNPs are those with minor allele
frequencies greater than 5%. Within the exon array, probesets are exon-level and transcript clusters are gene-level.
doi:10.1371/journal.pone.0009366.g001
SNPs in the Exon Array
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The exon array uses a set of short 25-mer probes to target each
feature of interest, together referred to as a probeset. The majority
of exon array probesets contain four probes. A gene-level
transcript cluster may have one or more exon-level probesets. In
total, ,1.4 million probesets and ,5.4 million probes under the
Affymetrix groupings of ‘‘core’’, ‘‘extended’’ and ‘‘full’’ were
included in our analysis. These probesets cover ,18,000 ‘‘core’’
transcript clusters, which have RefSeq-supported [31] annotations.
Mapping SNPs to the Exon Array
Common SNPs were those with MAF (minor allele frequency)
greater than 5%. Using the 1000 Genomes Project genotypic data,
in total, 510,957 (346,666 with MAF.0.05) SNPs in the CEU
samples and 783,071 (439,739 with MAF.0.05) SNPs in the YRI
samples (Supplemental Table S1) were found to be located in the
.5 million probes of the exon array. Among them, 173,639
(67,922 with MAF.0.05) SNPs in the CEU samples and 435,714
(154,764 with MAF.0.05) SNPs in the YRI samples were novel
ones relative to dbSNP v129 (Figure 1). Table 1 shows the
categories for those common SNPs with known functional
annotations (dbSNP v129) or those that could be imputed based
on their neighboring SNPs (Supplemental Table S2 for all SNPs).
SNP-Containing Probesets and Transcript Clusters
Focusing on common SNPs (MAF.0.05), among the ,1.4
million probesets on the exon array, 242,428 probesets (,17%)
(corresponding to 12,879 core-level transcript clusters) in the 57
CEU samples and 293,920 probesets (,21%) (corresponding to
13,700 core-level transcript clusters) in the 56 YRI samples were
found to contain SNPs (Table 2). Supplemental Table S3 lists the
statistics for both common and rarer SNPs. In addition, a majority
of the SNP-containing probesets harbored only one common SNP
(CEU: ,73%; YRI: ,69%). There is no chromosomal enrich-
ment in the number of affected probesets in either CEU or YRI
samples (binomial test, p,2.2610
216) (Supplemental Figure S1).
The complete lists of affected probesets in both populations are
provided in supplemental materials (Supplemental Tables S4, S5,
S6). In addition, Figure 2 shows the distribution of SNP locations
with the exon array 25-mer probes. Affymetrix classifies probesets
according to reliability. Since a substantial number of probesets
are classified as ‘‘extended’’ and ‘‘full’’, we determined the number
of affected probesets (i.e., containing SNPs with MAF .5%) in
each population under the various reliability groupings (Supple-
mental Table S7). To help evaluate how SNPs in probes may
impact gene-level summaries, we provide, in each population, the
number of affected probesets (i.e., containing probes with novel
SNPs such that MAF .5%) within each transcript cluster
(Supplemental Tables S8, S9). To facilitate studies using the array
at the probe level, we provide the genomic coordinates of probes
containing novel 1000 Genomes SNPs as well as the transcript
cluster ID, the probeset ID, each novel SNP’s genomic position,
and the SNP’s position along the probe sequence in each
population (Supplemental Tables S10, S11).
Comparison of Affected Probesets with the SNPinProbe
1.0 Database (dbSNP v129)
We previously built a database of SNP-containing probesets in
the exon array (SNPinProbes 1.0 [32]) based on dbSNP v129.
Approximately 350,000 SNP-containing probesets were filtered
out before summarizing gene expression intensities in the CEU
and YRI samples (Gene Expression Omnibus Accession:
GSE9703 [9], http://www.ncbi.nlm.nih.gov/projects/geo/). To
evaluate their potential impact on the previous gene expression
data, we compared our new list of SNP-containing probesets and
transcript clusters derived from the 1000 Genomes Project with
the ,350,000 affected probesets from the SNPinProbe database
(dbSNP v129). The probesets were further grouped based on the
number of SNPs in affected probes (e.g., 0, 1, 2, or more SNPs in a
particular probeset). Compared with our previous SNPinProbe
database [32] based on dbSNP v129, 72,291 and 186,563
probesets in the CEU and YRI samples, respectively, were found
to contain novel SNPs from the 1000 Genomes Project (Table 3).
In addition, 46,261 probesets in the CEU samples and 101,065
probesets in the YRI samples were found to contain both known
and novel SNPs. The proportions of new affected probesets
Table 1. Functional annotations of common SNPs in the exon array.
Function Class
a Description Count (CEU) Count (YRI)
coding-synonymous SNPs not causing changes in codons 5009 5110
frameshift SNPs causing frameshift in coding regions 48 32
intron SNPs located in introns 117070 122121
missense SNPs causing changes in codons 4519 4281
near-gene-3 SNPs close to the 39 of a gene 7547 7721
near-gene-5 SNPs close to the 59 of a gene 5275 4542
nonsense SNPs causing STOP codons 53 47
reference Same as the human genome reference 10189 10182
splice-3 SNPs at the 39-splice sites 2 3
splice-5 SNPs at the 59-splice sites 0 1
utr-3 SNPs located in the 39-untranslated regions 19843 21032
utr-5 SNPs located in the 59-untranslated regions 3132 2449
NA
b Unannotated 173979 262218
Total 346,666 439,739
a: based on dbSNP v129.
b: ‘‘NA’’ includes novel SNPs whose functions have not been classified or imputed.
doi:10.1371/journal.pone.0009366.t001
SNPs in the Exon Array
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the CEU samples and ,20% for the YRI samples.
Potential Influence of SNPs on Differentially Spliced
Probesets
Among the 782 differentially spliced probesets from a previous
study [9], 24 probesets were found to contain at least one novel
SNP in the CEU samples, and 94 probesets were found to contain
at least one novel SNP in the YRI samples. This analysis includes
both common (MAF .0 .05) and rare novel SNPs in affected
probesets, thus yielding the worst-case scenario. Therefore, up to
15% of the 782 identified probesets could be affected by the novel
SNPs from the 1000 Genomes Project. Supplemental Table S12
lists these potentially affected probesets, the number of novel
SNPs, and the number of rare SNPs (MAF ,0.05) among the
novel SNPs, in each population. A majority (,72%) of these
probesets contained one novel SNP. Therefore, among the
affected differentially spliced probesets, most would still yield
expression estimates after filtering for SNP-containing probes.
Potential lost coverage in these probesets is minimal. Figure 3
illustrates an example.
Discussion
Various factors (e.g., sample preparation, reagent quality) may
influence hybridization of target mRNA to microarray probes,
thus causing unreliable measurements of expression intensities.
Many of these technical factors can be optimized or controlled.
However, due to the existence of genetic variation among
individuals, polymorphisms in some samples may cause less
efficient hybridization to microarray probes, which are often
designed based on the reference sequences. Though a couple of
recent studies considered the effect of polymorphisms in probes
before summarizing expression data [8,9,33], it has been difficult
to comprehensively investigate the potential impact of common
SNPs on microarray expression platforms, partly because of the
lack of a detailed map of human genetic variation. The newly
released genotypic data from the 1000 Genomes Project provides
an opportunity to systematically evaluate the potential influence of
common genetic variants on these microarray platforms for their
use in human samples. Our aim, therefore, was to utilize the 1000
Genomes Project genotypic data to evaluate the distribution of
SNPs, especially those common SNPs (MAF.0.05) on the
Affymetrix exon array, which has recently been used in gene
expression [8], transcript isoform variation [9,33] as well as
numerous pharmacogenomic studies [16,17]. Because of the
Table 2. Probesets containing common SNPs based on the
1000 Genomes Project data.
Population 0 SNPs 1 SNP 2 SNPs $3 SNPs
Total Affected
Probesets
CEU 1183219 177336 40578 24514 242428
YRI 1131727 204650 54179 35091 293920
doi:10.1371/journal.pone.0009366.t002
Figure 2. Distribution of SNP locations with the 25-mer exon array probes. Each bin is 5 nt. Left is 59 and right is 39. Common SNPs
(MAF.0.05) are included. MAF: minor allele frequency.
doi:10.1371/journal.pone.0009366.g002
SNPs in the Exon Array
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systematic biases and data variability may need to be considered
when utilizing these data [34]. Focusing on common SNPs,
therefore, could potentially alleviate the problem of errors in base
calling.
Focusing on common SNPs with MAF.0.05, overall, ,17%
and ,21% probesets out of the total ,1.4 million probesets were
found to contain at least one common SNP in their probes for the
CEU and YRI samples, respectively (Table 2). The YRI samples
had many more SNP-containing probesets than the CEU samples,
consistent with the hypothesis that Africans are an older
population with more genetic variation [35]. It has been observed
that probe-level expression can have significant changes when a
polymorphism is present near the middle of the target area (i.e.,
between positions 6 and 21 of a 25-mer probe) [20]. The
distribution of the SNPs–both novel (with MAF.0.05) as well as
novel in general–in the exon array probes appeared to be evenly
distributed across the probe length (Figure 2), suggesting that
roughly 60% (corresponding to bins 2–4 in Figure 2) of the SNP-
containing probes could be affected more significantly by the
presence of SNPs. A majority of those known SNPs (based on
dbSNP v129) and the novel SNPs, whose positions allowed reliable
functional imputation, are located in the intronic regions (CEU:
,68%; YRI: ,69%) (Table 1).Those intronic SNP-containing
probes may, therefore, particularly affect the measurement of
expression of a novel exon not present in the reference sequence.
Similarly, for example, the SNPs located in UTRs may affect the
detection of alternative initiation or termination.
Figure 3. A differentially spliced probeset that could be affected by novel SNPs. The probeset 3017096 (chr7: 102526627–102527377) has
a novel SNP (chr7: 102526628) in the CEU samples. The probeset was originally found to be differentially spliced between the CEU and YRI samples.
UCSC Genome Browser (http://genome.ucsc.edu/) was used to plot the genomic positions (hg18, March, 2006) of the probeset in relation to the
other probesets for the ARMC10 gene. This novel SNP lies within the probe chr7:102526627–102526651.
doi:10.1371/journal.pone.0009366.g003
Table 3. Comparison with the SNPinProbe database(dbSNP
v129).
Population Class Novel Known Both Total
CEU 1 SNP 59462 159789 0 219251
2 SNPs 8677 31472 19303 59452
$3 SNPs 4152 11706 26958 42816
Total 72291 202967 46261 321519
YRI 1 SNP 142719 125199 0 267918
2 SNPs 30529 22148 40422 93099
$3 SNPs 13315 6509 60643 80467
Total 186563 153856 101065 441484
Both: affected by novel and known SNPs.
doi:10.1371/journal.pone.0009366.t003
SNPs in the Exon Array
PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9366Conceptually, the 1000 Genomes Project genotypic data aims to
cover both known SNPs and novel SNPs. Our next aim was to
evaluate how the 1000 Genomes Project genotypic data was
compared with the known dbSNP data. Particularly, we previously
built the SNPinProbe database [32] of all affected exon array
probesets based on the then current dbSNP v129. Both gene-level
[8] and exon-level [9] expression data taking into account these
SNP-containing probesets have been made public. Therefore, a
comparison between what we found with the 1000 Genomes
Project genotypic data and the SNPinProbe database [32] would
allow us to evaluate the potential influence of novel SNPs on our
previous gene expression datasets [8,9] and the results based on
those expression data (e.g., pharmacogenomic discoveries [16,17]).
The SNPinProbe database is comprised of ,350,000 affected
probesets (combined CEU and YRI samples) [32]. In contrast,
using the 1000 Genomes Project data, ,320,000 (,242,000 with
MAF.0.05) and ,440,000 (,294,000 with MAF.0.05) affected
probesets were identified for the CEU and YRI samples,
respectively. If the two populations were combined as the
SNPinProbe database did, 506,872 probesets would be identified
to contain at least one SNP. Therefore, ,157,000 more probesets
would be identified using the 1000 Genomes Project data,
suggesting that interpretation of any association results including
these probesets should take into account the potential confounding
effect of polymorphisms.
To further illustrate the potential effect of any probesets affected
by novel SNPs as well as to demonstrate an application of this new
resource of SNP-containing exon array probesets, we examined a
list of 782 differentially spliced probesets between the CEU and
YRI samples [9]. Among the 782 identified probesets, ,15%
would be found to contain at least one novel SNP in one
population. For example, the probeset 3017096 (chr7:
102526627–102527377), which interrogates ARMC10 together
with probesets 3017094, 3017095, and 3017088, has a novel SNP
(chr7: 102526628) in the CEU samples (Figure 3). The
identification of its alternative splicing between the two popula-
tions, therefore, should be cautiously evaluated. For this particular
study (alternative splicing between human populations [9]) though,
it appeared that most of the identified differentially spliced
probesets (,85%) would be free of any known or novel SNPs. Of
the remaining probesets (,15%), a majority (,72%) would
nevertheless allow expression estimates derived from probes
unaffected by SNPs. In addition, ARMC10 showed evidence of
being differentially spliced between CEU and YRI (p=0.015, two-
tailed t-test) when the probeset 3017096 is included, but shows no
evidence (p=0.48, two-tailed t-test) when the SNP-containing
probes are excluded.
In summary, due to the amount of targets on a single
microarray, obviously, a systematic experimental evaluation of
the effects of polymorphisms on gene expression would be
extremely difficult. Though statistical approaches may be used to
adjust these effects in certain cases [21], a comprehensive
catalogue of the SNP affecting microarray probes, however, can
allow researchers to immediately evaluate previous findings based
on these gene expression data, facilitate future data re-analysis
efforts (e.g., removing affected data points), and benefit the design
of follow-up experiments (e.g., to prioritize candidates by avoiding
those potentially affected genes). In addition, our analysis showed
an application of the newly released 1000 Genomes Project
genotypic data which clearly will benefit the entire community of
biomedical research (e.g., pharmacogenomics [36]) by providing a
detailed map of human genetic variation. Finally, similar analyses
could be performed on other microarray platforms in the future to
allow a cross-platform comparison.
Materials and Methods
Affymetrix Exon Array Annotations
The probe, probeset (exon-level) and transcript cluster (gene-
level) annotations for the Affymetrix GeneChip Human Exon
1.0ST array were downloaded from the Affymetrix NetAffx
Analysis Center (http://www.affymetrix.com/analysis/index.affx)
(NetAffy build 27). The human genome reference version is NCBI
build 36 (hg18, March, 2006).
The 1000 Genomes Project Data
The 1000 Genomes Project was launched in January, 2008.
The first set of SNP calls of four genomes of HapMap LCLs (3
samples from a CEU parents-child trio and 1 YRI sample) were
released Dec., 2008 from the high coverage (.206) pilot. The
SNP calls on the CEU trio (father: NA12891; mother: NA12892;
child: NA12878) were based on the Illumina platform (mostly
paired end 35 bp reads). The SNP calls on the YRI sample
(NA19240) were detected using the Applied Biosystems SOLiD
(Sequencing by Oligo Ligation and Detection) sequencing
platform. More recently, sequence data and SNP calls on .600
genomes (April, 2009) in the low coverage pilot were also released.
We downloaded the 1000 Genomes Project data of the currently
available 57 CEU samples and 56 YRI samples including FASTQ
files (nucleotides and quality assessments), SNP calls, and Binary
Simple Alignment/Map files (BAM) (ftp://ftp-trace.ncbi.nih.gov/
1000genomes), as well as FASTA files for the human genome
reference assembly (ftp://ftp.ensembl.org/pub/current_fasta/
homo_sapiens/dna/). We wrote our own Extractor (for the
FASTQ files) and Analyzer (for summarization), and invoke the
tool (SAMtools, http://samtools.sourceforge.net/samtools-c.
shtml) for the (binary) Sequence Alignment/Map format (for
multiple alignments) used by the Sanger Institute. Summary
analysis data are stored in a relational data store (MySQL, http://
www.mysql.com).
Mapping 1000 Genomes SNPs to the Exon Array
The genomic regions of the probesets, along with transcript
cluster annotations, were loaded into MySQL to be easily queried.
The genomic positions of .9 million SNPs in the 57 CEU samples
and of .13 million SNPs in the 56 YRI samples in the 1000
Genomes data release were mapped to dbSNP v129 and RefSeq
genes based on the reference assembly(build36). Thisfacilitated the
annotation of known SNPs with rs identifier (dbSNP v129), RefSeq
[31] alleles, functional class, and host gene, as well as enabled the
identification of novel SNPs. We imputed the host gene for
intragenic SNPs based on the genomic coordinates found in RefSeq
[31] Gene, as well as the functional class for novel SNPs in the
following cases: (a) a SNP with flanking 59-UTR (untranslated
region)neighborsannotatedto the same gene was assigned thesame
functional designation; similarly, for 39-UTR (b) a SNP with
flanking ‘‘near-gene-59’’ or ‘‘near-gene-39’’ neighbors annotated to
the same gene (within 2000 bases) received the same functional
designation. Genome-wide queries were then performed between
the .17 million SNPs and the ,1.4 million probesets.
Potential Influence on Differentially Spliced Probesets
We previously identified a list of 782 differentially spliced
probesets between the CEU and YRI samples [9] by filtering out
, 600,000 SNP-containing probes in ,350,000 probesets as in
the SNPinProbe database [32]. The exon array data is MIAME
compliant and that the raw data has been deposited in the NCBI
Gene Expression Omnibus (GSE9703, http://www.ncbi.nlm.nih.
gov/geo/). To evaluate the potential influence of any novel SNPs
SNPs in the Exon Array
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probesets with our newly identified SNP-containing probesets.
Particularly, probesets affected by novel SNPs in only one
population (either CEU or YRI) were compared with the 782
probesets, assuming a comparison between the CEU and YRI
samples could be especially biased due to the existence of SNPs in
one population.
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